Navigation Links
Tengion to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
Date:1/30/2008

EAST NORRITON, Pa., Jan. 30 /PRNewswire/ -- Tengion Inc., a clinical stage regenerative medicine company focused on the development of neo-organs and neo-vessels, announced today that Steven Nichtberger, M.D., President and Chief Executive Officer, will be presenting at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on Tuesday, February 5, 2008 at 9:20 a.m. EST. The conference will be held at the Grand Hyatt Hotel in New York City.

About Tengion

Tengion, a clinical stage biotechnology company, has pioneered the Autologous Organ Regeneration Platform(TM) that catalyzes the body's innate ability to regenerate. Tengion's neo-organs and neo-tissues in development, such as bladders and vessels, combine biocompatible materials and a patient's own (autologous) cells to regenerate diseased and failing organs and tissues. Tengion's product candidates have the potential to cure -- rather than treat -- organ and tissue failure, enabling people to lead healthier lives without donor transplants or the side effects of related therapies. For more information on the company and current clinical trials, visit Tengion online at: http://www.tengion.com.


'/>"/>
SOURCE Tengion Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Preclinical Efficacy Data Demonstrate Ability of Tengions Neo-Bladder Augment to Restore Bladder Function
2. 3SBio Inc. to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
3. BioMarin to Present at the Merrill Lynch 2008 Global Healthcare Conference
4. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
5. Thermo Fisher Scientific to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
6. Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections
7. Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
8. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
9. Kendle to Present at the Wachovia 2008 Healthcare Conference
10. Phytomedics Inc. to Present at Wachovia 2008 Healthcare Conference
11. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... Bioptix, Inc. (Nasdaq: ... January 14, 2017 the Board of Directors of the ... terminate certain employees associated with the September 2016 acquisition ... terminations on January 16, 2017 and terminations are expected ... pay severance benefits in certain circumstances of up to ...
(Date:1/21/2017)...   Boston Biomedical , an industry leader in ... stemness pathways, today presented data from two clinical studies ... American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium ... In a Phase Ib/II study of napabucasin – ... stemness pathways by targeting STAT3 – colorectal cancer (CRC) ...
(Date:1/20/2017)... -- Stock-Callers.com explores the Biotech industry to ... recent performances of select equities. In this morning,s lineup ... Abeona Therapeutics Inc. (NASDAQ: ABEO ), Theravance ... Therapeutics Inc. (NASDAQ: SAGE ). According to ... market size is expected to reach $604.40 billion by 2020 due to ...
(Date:1/20/2017)... http://www.Financialbuzz.com - According ... causes of death worldwide. There were 8.2 million cancer ... related deaths increased gradually over time, the death rates ... various cancers continues to drive demand of biological therapies ... Market Insights, Inc. cancer biological therapy market size was USD ...
Breaking Biology Technology:
(Date:1/12/2017)... PUNE, India , January 12, 2017 A new ... - 2022," projects that the global biometric technology market is expected to generate revenue ... 2022. Continue Reading ... ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) ...
(Date:1/6/2017)... , Jan. 5, 2017  Delta ID Inc., a ... scanning technology for automotive at CES® 2017. Delta ID ... ) to demonstrate the use of iris scanning as ... authenticate the driver in a car, and as a ... driving experience. Delta ID and Gentex will ...
(Date:12/22/2016)... SuperCom (NASDAQ:   SPCB ... e-Government, Public Safety, HealthCare, and Finance sectors announced today that Leaders ... to implement and deploy a community-based supportive services program to reduce ... , further expanding its presence in the state. ... This new program, which is expected ...
Breaking Biology News(10 mins):